With the FDA's approval of GlaxoSmithKline's tafenoquine, global health experts will at last have access to a long-awaited new treatment for Plasmodium vivax recurrence. Much-needed novel treatments for the more common Plasmodium falciparum are in phase II trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Malaria medicine box expands. Nat Rev Drug Discov 17, 693–695 (2018). https://doi.org/10.1038/nrd.2018.156
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.156